Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo-controlled study

This publication has 24 references indexed in Scilit:

• Selective inhibition of T-type Ca2+ channels by Ro 40-5967.
  Circulation Research, 1994
• Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries
  Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1993
• Ro 40–5967: A New Nondihydropyridine Calcium Antagonist
  Cardiovascular Drug Reviews, 1991
• The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts
  Cardiovascular Drugs and Therapy, 1990
• Amlodipine
  Cardiovascular Drug Reviews, 1990
• Effects of Ro 40-5967, a Novel Calcium Antagonist, on Myocardial Function During Ischemia Induced by Lowering Coronary Perfusion Pressure in Dogs: Comparison with Verapamil
  Journal of Cardiovascular Pharmacology, 1989
• The pharmacokinetic profile of amlodipine
  American Heart Journal, 1989
• In Vitro Pharmacologic Profile of Ro 40-5967, a Novel Ca2+ Channel Blocker with Potent Vasodilator but Weak Inotropic Action
  Journal of Cardiovascular Pharmacology, 1989
• Calcium antagonists for chronic stable angina pectoris
  The American Journal of Cardiology, 1987
• Calcium-channel blockers: Pharmacologic considerations
  American Heart Journal, 1982